The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR-Reference-Cited by-同舟云学术

The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR

Published:2007-04-25 Issue:6 Volume:8 Page:718-732
ISSN:1398-9219
Container-title:Traffic
language:en
Short-container-title:

Author:

Nassoury Nasha,Blasiole Daniel A.,Tebon Oler Angie,Benjannet Suzanne,Hamelin Josée,Poupon Vivianne,McPherson Peter S.,Attie Alan D.,Prat Annik,Seidah Nabil G.

Publisher

Wiley

Subject

Cell Biology,Genetics,Molecular Biology,Biochemistry,Structural Biology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0854.2007.00562.x/fullpdf

Reference47 articles.

1. Human and mouse proteases: a comparative genomic approach;Puente;Nat Rev Genet,2003

2. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides;Seidah;Brain Res,1999

3. Precursor convertases in the secretory pathway, cytosol and extracellular milieu;Seidah;Essays Biochem,2002

4. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation;Seidah;Proc Natl Acad Sci U S A,2003

5. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol;Benjannet;J Biol Chem,2004

Cited by 213 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9;European Journal of Clinical Investigation;2024-06-26

2. Phytaspase Does Not Require Proteolytic Activity for Its Stress-Induced Internalization;International Journal of Molecular Sciences;2024-06-19

3. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08

4. Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review;Annals of Medicine & Surgery;2024-01-03

5. Novel ASO therapeutic target designed against hyperlipidemia via PCSK9 knockdown;Biomedicine & Pharmacotherapy;2024-01